Becton Dickinson and Co

News & Events zu Becton Dickinson and Co (BDX)

$187.620

+0.094 (+0.05%)Zum Schluss

BDX-News

BDX-Events

8/12 07:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

Becton Dickinson announced the completion of enrollment in the PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias. Following completion of the primary endpoint assessments, data from the study are expected to support a planned submission to the FDA as part of the regulatory pathway for this indication.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten